(See all James M. Burns' publications in PubMed.)
"Inclusion of an optimized Plasmodium falciparum merozoite surface protein 2-based antigen in a trivalent, multi-stage malaria vaccine"
Eacret JS, Parzych EM, Gonzales DM and Burns JM Jr.
J. Immunol. 206: 1 (2021)
"Maintaining immunogenicity of blood-stage and sexual stage subunit malaria vaccines when formulated in combinations"
Parzych EM, Miura K, Long CA and Burns JM Jr.
PLoS One, 15:e0232355 (2020)
"Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody"
Eacret JS, Gonzales DM, Franks RG and Burns JM Jr.
Scientific Reports, 9:9022 (2019)
"Evaluation of a Plasmodium-Specific Carrier Protein to Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate"
Parzych EM, Miura K, Ramanathan A, Long CA and Burns JM Jr.
Infection and Immunity, 86:e00486-17 (2018)
"Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys"
Burns JM Jr., Miura K, Sullivan J, Long CA and Barnwell JW
Malaria J. 15:159 (2016)
"Host erythrocyte environment influences the localization of exported protein 2, an essential component of the Plasmodium translocon"
Meibalan E, Comunale MA, Lopez AM, Bergman LW, Mehta A, Vaidya AB and Burns JM Jr.
Eukaryotic Cell. 14:371-384 (2015)
"A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies"
Alaro JR, Partridge A, Miura K, Diouf A, Lopez AM, Angov E, Long CA and Burns JM Jr.
Infection and Immunity Immun. 81:3843-3854 (2013)
"Remarkable stability in patterns of blood-stage gene expression during episodes of non-lethal Plasmodium yoelii malaria"
Cernetich-Ott A, Daly TM, Vaidya AB, Bergman LW and Burns JM Jr.
Malaria J. 11:265 (2012)
"Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8"
Alaro JR, Angov E, Lopez AM, Zhou H, Long CA and Burns JM Jr.
Infect. Immun. 80:2473-2484 (2012)
"Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection"
Alaro JA, Lynch MM and Burns JM Jr.
Vaccine, 28:6876-6884 (2010)
"Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor reduce the severity of blood-stage malaria"
Thorat S, Daly TM, Bergman LW and Burns JM Jr.
Infection and Immunity, 78:5151-5162 (2010)
Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-γ-dependent responses induced by vaccination and/or challenge infection
Petritus PM and Burns JM Jr.
The Journal of Immunology, 180:444 (2008)
"Enhanced protection against malaria by a chimeric merozoite surface protein vaccine"
Shi Q, Lynch MM, Romero M and Burns JM Jr.
Infection and Immunity, 75:1349 (2007)
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites
Shi Q, Cernetich A, Daly TM, Galvan G, Vaidya AB, Bergman LW and Burns JM Jr.
Infection and Immunity, 73:6363 (2005)
"Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen-1 and merozoite surface protein-1 does not require IFN-γ or IL-4"
Burns JM Jr., Flaherty JM, Nanavati P and Weidanz WP
Infection and Immunity, 72: 5605 (2004)
Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1
Burns JM Jr., Flaherty PR, and WP Weidanz
Vaccine, 21:1843 (2003)
A protective GPI-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains
Burns JM Jr., Belk CC, and PD Dunn.
Infection and Immunity, Vol. 68: 6189 (2000)